FIELD: medicine, oncology.
SUBSTANCE: method involves administration of bleomycin and erythropoietin simultaneously in patients. Invention can be used for decreasing pulmonary cytotoxicity in patients treated with bleomycin. Invention provides improving functioning lung in patients of this category.
EFFECT: valuable medicinal properties of erythropoietin.
4 cl, 2 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-MESOTHELIN IMMUNOCONJUGATES AND USE THEREOF | 2010 |
|
RU2575612C2 |
| COMBINED THERAPY USING INHIBITORS OF TYROSINE KINASE RECEPTORS AND INHIBITORS OF ANGIOGENESIS | 2001 |
|
RU2292904C2 |
| COMBINATION AND METHODS FOR INTRODUCING THERAPEUTIC AGENTS AND COMBINED THERAPY | 2006 |
|
RU2452482C2 |
| APPLYING EPOTILONES FOR CANCER TREATMENT | 1999 |
|
RU2242229C2 |
| METHOD OF TREATING DISEASES BY VEGF ANTAGONISTS | 2006 |
|
RU2414924C2 |
| COMBINATIONS AND METHODS FOR THERAPEUTIC AGENTS INTRODUCTION AND COMBINED THERAPY | 2012 |
|
RU2632103C2 |
| COMBINED IMMUNOTHERAPEUTIC APPROACH TO CANCER TREATMENT | 2015 |
|
RU2716821C2 |
| METHOD FOR ENHANCING EFFECTIVENESS OF ANTITUMOR AGENTS | 2000 |
|
RU2271829C2 |
| ANTIBODIES, CONTAINING THERAPEUTIC TPO/EPO MIMETIC PEPTIDES | 2010 |
|
RU2559526C2 |
| COMBINED DRUG FOR TREATMENT OF TUMOR DISEASES | 2002 |
|
RU2291710C2 |
